853 / 1851
RT + adjuv PCV vs RT alone: EORTC 26951
368 AO or AOA randomly assigned to receive RT 59.4 Gy/33 fr + adjuvant PCV x 6 vs RT alone
Long term results: increased OS and PFS in favor of patients receiving PCV in the overall population
After molecular stratification
1p/19q codeleted tumors derived major benefit
from adjuvant
PCV, whereas
non codeleted tumors has derived NO benefit from PCV
Overall Survival
Overall Survival
Overall Survival
Overall population
1p/19q CODELETED
non CODELETED
Median OS time:
42.3 vs 30.6 months
Median OS time:
25 vs 21 months
Median OS time:
n.r vs 112 months
Van den Bent MJ. et al. JCO 2013;31